BNP Paribas Financial Markets
RNAC icon

BNP Paribas Financial Markets’s Cartesian Therapeutics RNAC Stock Holding History

BNP Paribas Financial Markets’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.2K Buy
9,950
+7,536
+312% +$53.7K ﹤0.01% 4593
2025
Q4 		$17.4K Buy
2,414
+174
+8% +$1.41K ﹤0.01% 5055
2025
Q3 		$22.9K Buy
2,240
+862
+63% +$9.69K ﹤0.01% 4884
2025
Q2 		$14.3K Buy
1,378
+360
+35% +$3.83K ﹤0.01% 4739
2025
Q1 		$13.4K Sell
1,018
-627
-38% -$11.2K ﹤0.01% 4647
2024
Q4 		$29.5K Sell
1,645
-6
-0.4% -$121 ﹤0.01% 4612
2024
Q3 		$26.6K Buy
1,651
+909
+123% +$14.2K ﹤0.01% 3722
2024
Q2 		$20K Sell
742
-1,229
-62% -$29.3K ﹤0.01% 3641
2024
Q1 		$38.4K Buy
1,971
+828
+72% +$17.6K ﹤0.01% 3600
2023
Q4 		$23.6K Buy
1,143
+101
+10% +$3.02K ﹤0.01% 3652
2023
Q3 		$33.1K Buy
1,042
+31
+3% +$1.04K ﹤0.01% 3519
2023
Q2 		$34K Buy
1,011
+969
+2,307% +$34.7K ﹤0.01% 3543
2023
Q1 		$1.77K Sell
42
-9
-18% -$423 ﹤0.01% 3641
2022
Q4 		$1.73K Buy
51
+28
+122% +$1.19K ﹤0.01% 3750
2022
Q3 		$1.15K Sell
23
-1,152
-98% -$63.3K ﹤0.01% 4411
2022
Q2 		$46.2K Sell
1,175
-9,690
-89% -$287K ﹤0.01% 3580
2022
Q1 		$401K Sell
10,865
-529
-5% -$33.1K ﹤0.01% 2868
2021
Q4 		$1.11M Buy
11,394
+10,627
+1,386% +$1.14M ﹤0.01% 2510
2021
Q3 		$95.7K Buy
767
+525
+217% +$63.4K ﹤0.01% 3289
2021
Q2 		$30.3K Sell
242
-357
-60% -$42.5K ﹤0.01% 3424
2021
Q1 		$81.2K Buy
599
+168
+39% +$20.9K ﹤0.01% 3444
2020
Q4 		$39.1K Sell
431
-114
-21% -$9.88K ﹤0.01% 3662
2020
Q3 		$40.6K Buy
545
+460
+541% +$35.2K ﹤0.01% 3565
2020
Q2 		$7.23K Buy
85
+84
+8,400% +$7.61K ﹤0.01% 3854
2020
Q1 		$87 Hold
1
– – ﹤0.01% 4222
2019
Q4 		$86 Sell
1
-126
-99% -$6.08K ﹤0.01% 4338
2019
Q3 		$6.65K Hold
127
– – ﹤0.01% 4229
2019
Q2 		$6.8K Sell
127
-121
-49% -$8.25K ﹤0.01% 4190
2019
Q1 		$17.6K Buy
248
+238
+2,380% +$15.1K ﹤0.01% 3930
2018
Q4 		$801 Sell
10
-9
-47% -$2.05K ﹤0.01% 3950
2018
Q3 		$8.89K Sell
19
-2
-10% -$804 ﹤0.01% 3793
2018
Q2 		$8.15K Sell
21
-83
-80% -$29.4K ﹤0.01% 3879
2018
Q1 		$31.8K Buy
104
+7
+7% +$1.99K ﹤0.01% 3770
2017
Q4 		$28.6K Buy
97
+18
+23% +$7.87K ﹤0.01% 3895
2017
Q3 		$43.1K Buy
79
+38
+93% +$20.2K ﹤0.01% 3220
2017
Q2 		$24.2K Buy
41
+39
+1,950% +$17.2K ﹤0.01% 3551
2017
Q1 		$788 Sell
2
-8
-80% -$3.37K ﹤0.01% 3749
2016
Q4 		$5.11K Buy
10
+4
+67% +$2.34K ﹤0.01% 3701
2016
Q3 		$2.61K Buy
+6
New +$2.35K ﹤0.01% 3449

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BNP Paribas Financial Markets's RNAC Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Cartesian Therapeutics (RNAC) stake by 312% in Q1 2026, buying an estimated $53.7K and bringing the position to 9,950 shares worth $61.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4593.

BNP Paribas Financial Markets first reported a position in RNAC in Q3 2016 and has held it in 39 quarters since. The position peaked at $1.11M in Q4 2021. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • BNP Paribas Financial Markets held 9,950 shares of Cartesian Therapeutics worth $61.2K as of Q1 2026.
  • BNP Paribas Financial Markets bought 7,536 Cartesian Therapeutics shares in Q1 2026, an estimated $53.7K.
  • Cartesian Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #4593 holding.
  • BNP Paribas Financial Markets first reported a position in Cartesian Therapeutics in Q3 2016 and has held it in 39 quarters since.
  • BNP Paribas Financial Markets's Cartesian Therapeutics position peaked at $1.11M in Q4 2021.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.